Home / Publications / Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity

Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity

Egor Vladimirovich Verbitskiy 1, 2
Egor Vladimirovich Verbitskiy
, 
Svetlana Anatol'evna Baskakova 1
Svetlana Anatol'evna Baskakova
, 
Danila Vladimirovich Belyaev 1, 3
Danila Vladimirovich Belyaev
, 
Diana Vladimirovna Vakhrusheva 3
Diana Vladimirovna Vakhrusheva
, 
Natalya I Eremeeva 3
Natalya I Eremeeva
, 
Gennady Leonidovich Rusinov 1, 2
Gennady Leonidovich Rusinov
, 
Valery Nikolaevich Charushin 1, 2
Valery Nikolaevich Charushin
10.1016/j.mencom.2021.03.021
Published 2021-03-03
Communication , Volume 31, Issue 2, 210-212
13
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Verbitskiy E. V. et al. Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity // Mendeleev Communications. 2021. Vol. 31. No. 2. pp. 210-212.
GOST all authors (up to 50) Copy
Verbitskiy E. V., Baskakova S. A., Belyaev D. V., Vakhrusheva D. V., Eremeeva N. I., Rusinov G. L., Charushin V. N. Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity // Mendeleev Communications. 2021. Vol. 31. No. 2. pp. 210-212.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2021.03.021
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2021.03.021
TI - Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity
T2 - Mendeleev Communications
AU - Verbitskiy, Egor Vladimirovich
AU - Baskakova, Svetlana Anatol'evna
AU - Belyaev, Danila Vladimirovich
AU - Vakhrusheva, Diana Vladimirovna
AU - Eremeeva, Natalya I
AU - Rusinov, Gennady Leonidovich
AU - Charushin, Valery Nikolaevich
PY - 2021
DA - 2021/03/03
PB - Mendeleev Communications
SP - 210-212
IS - 2
VL - 31
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Verbitskiy,
author = {Egor Vladimirovich Verbitskiy and Svetlana Anatol'evna Baskakova and Danila Vladimirovich Belyaev and Diana Vladimirovna Vakhrusheva and Natalya I Eremeeva and Gennady Leonidovich Rusinov and Valery Nikolaevich Charushin},
title = {Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity},
journal = {Mendeleev Communications},
year = {2021},
volume = {31},
publisher = {Mendeleev Communications},
month = {Mar},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2021.03.021},
number = {2},
pages = {210--212},
doi = {10.1016/j.mencom.2021.03.021}
}
MLA
Cite this
MLA Copy
Verbitskiy, Egor Vladimirovich, et al. “Renaissance of 4-(5-nitrofuran-2-yl)-5-arylamino substituted pyrimidines: microwave-assisted synthesis and antitubercular activity.” Mendeleev Communications, vol. 31, no. 2, Mar. 2021, pp. 210-212. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2021.03.021.

Keywords

anti-mycobacterial activity
Buchwald–Hartwig amination
cross-coupling reactions
nitrofurans
pyrimidines

Abstract

The Buchwald–Hartwig cross-coupling of 5-bromo-4-(furan-2-yl)pyrimidine with various anilines afforded the corresponding new 5-(arylamino)pyrimidines, the reaction being accelerated by microwave irradiation. Most of the obtained compounds proved to possess a high bacteriostatic in vitro effect against Mycobacterium tuberculosis H37Rv, Neisseria gonorrhoeae, and Staphylococcus aureus including Methicillin-resistant strain, which is stronger than that of the commercial drug Spectinomycin.

References

1.
Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review
Di Gennaro F., Pizzol D., Marotta C., Antunes M., Racalbuto V., Veronese N., Smith L.
International Journal of Environmental Research and Public Health, 2020
3.
Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial
Wu X., Yu K., Wang Y., Xu W., Ma H., Hou Y., Li Y., Cai B., Zhu L., Zhang M., Hu X., Gao J., Wang Y., Qin H., Wang W., et. al.
Engineering, 2020
5.
Molecular basis of COVID-19 pathogenesis
Novikov F.N., Stroylov V.S., Svitanko I.V., Nebolsin V.E.
Russian Chemical Reviews, 2020
7.
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis
Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFadden D.R., Soucy J.R., Daneman N.
Clinical Microbiology and Infection, 2020
8.
Global Tuberculosis Report 2019, WHO Report Reveals, WHO Media Centre, 2019, https://www.who.int/tb/publications/global_report/en.
9.
Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis.
Makarov V., Salina E., Reynolds R.C., Kyaw Zin P.P., Ekins S.
Journal of Medicinal Chemistry, 2020
11.
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
Ginsberg A.M., Laurenzi M.W., Rouse D.J., Whitney K.D., Spigelman M.K.
Antimicrobial Agents and Chemotherapy, 2009
12.
OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice
Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M.
PLoS Medicine, 2006
13.
Structure−Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4- and 5-Nitroimidazoles
Kim P., Zhang L., Manjunatha U.H., Singh R., Patel S., Jiricek J., Keller T.H., Boshoff H.I., Barry C.E., Dowd C.S.
Journal of Medicinal Chemistry, 2009
14.
Verbitskiy E.V., Baskakova S.A., Gerasimova N.A., Evstigneeva N.P., Zil’berberg N.V., Kungurov N.V., Kravchenko M.A., Rusinov G.L., Chupakhina O.N., Charushin V.N.
Mendeleev Communications, 2018
15.
Verbitskiy E.V., Dinastiya E.M., Eltsov O.S., Zhilina E.F., Schepochkin A.V., Rusinov G.L., Chupakhin O.N., Charushin V.N.
Mendeleev Communications, 2020
16.
Halogenation as a tool to tune antimicrobial activity of peptoids
Molchanova N., Nielsen J.E., Sørensen K.B., Prabhala B.K., Hansen P.R., Lund R., Barron A.E., Jenssen H.
Scientific Reports, 2020
18.
Development of new antituberculosis drugs among of 1,3- and 1,4-diazines. Highlights and perspectives
Verbitskiy E.V., Rusinov G.L., Charushin V.N., Chupakhin O.N.
Russian Chemical Bulletin, 2019
19.
10.1016/j.mencom.2021.03.021_bib0095
Sharma
Int. J. Med. Chem., 2014